Moderna Stock Jumps 9% as FDA Clears Key Hurdle for mRNA Flu Shot
16 Jun 2026 · 20:06 UTC · CoinCentral RSS Feed · Original source
Read original at CoinCentral RSS Feed →
Summary
Moderna stock jumped 9.1% after FDA briefing documents showed no major deficiencies in its mFlusiva mRNA flu vaccine candidate. The FDA's advisory committee (VRBPAC) is scheduled to vote on June 18 on whether the benefits of mFlusiva outweigh its risks for adults 50 and older. If approved, mFlusiva would be the first mRNA-based seasonal flu vaccine on the market.
Why it matters
Moderna's vaccine approval developments affect only traditional biotech/pharma investors and sentiment, not cryptocurrency market participants or blockchain adoption trends. There is no mechanistic link between mRNA flu vaccine approval progress and crypto asset valuations. Cryptocurrency markets operate independently from individual pharmaceutical stocks and clinical trial outcomes. Any minimal market impact would be negligible and driven only by broad market sentiment shifts that are highly unlikely to result from a single drug approval announcement in the biotech sector. The source credibility is moderate since CoinCentral primarily covers crypto, making this off-topic coverage less reliable than a dedicated pharma news outlet.
Expected impact
This article covers Moderna's FDA approval progress for mFlusiva, an mRNA-based seasonal flu vaccine for adults 50 and older. The advisory committee vote is scheduled for June 18. This is purely pharmaceutical/biotech sector news with no direct relevance to cryptocurrency markets. While Moderna is a publicly-traded company, drug pipeline developments do not impact Bitcoin, Ethereum, or altcoin valuations. The article's publication on CoinCentral appears to be out-of-scope content for a cryptocurrency news outlet. No meaningful cryptocurrency market impact is expected from this announcement.